NCT03230292View on ClinicalTrials.gov

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 3, 2017

Primary Completion Date

March 6, 2019

Study Completion Date

March 6, 2019

Conditions

Chronic Plaque Psoriasis

Interventions

DRUG

Bimekizumab

Bimekizumab will be administered subcutaneously in 2 different doses.

Trial Locations (10)

27265

Ps0018 701, High Point

43209

Ps0018 704, Bexley

Unknown

Ps0018 101, Carlton

Ps0018 103, East Melbourne

Ps0018 102, Kogarah

Ps0018 104, Woolloongabba

Ps0018 201, Ajax

Ps0018 203, London

Ps0018 202, Windsor

Ps0018 501, Chisinau

All Listed Sponsors

lead

UCB Biopharma SRL

INDUSTRY

NCT03230292 - A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis | Biotech Hunter | Biotech Hunter